[1]
Vinsova, J. Biologically active Benzoxazoles. Ceska Slov. Farm., 2003, 52(6), 282-290.
[2]
Demmer, C.S. Benzoxazoles and oxazolopyridines in medicinal chemistry studies. Eur. J. Med. Chem., 2014, 97, 778-785.
[3]
Knights, K. Cassidy, m.; Drew, R. Benoxaprofen induced toxicity in isolated rat hepatocytes. Toxicology, 1986, 40, 327-339.
[4]
Sacchi, C.; Magni, F.; Toia, A.; Cazzaniga, F.; Galli, G.; Berti, F. Flunoxaprofen, a new non-steroidal anti-inflammatory drug, does not interfere with prostaglandin synthesis in rat gastric mucosa. Pharmacol. Res., 1989, 21, 177-182.
[5]
Breiner, R.; McComb, R.; Holtman, V. Chlorzoxazone mimics apobarbital in Toxilab drug screen. Clin. Chem., 1984, 30, 1719.
[6]
Kobayashi, J.; Madono, T.; Shigemori, H. Nakijinol, A novel sesquiterpenoid sontaining a benzoxazole ring from an okinawan sponge. Tetra. Lett., 1995, 36, 5589-5590.
[7]
Ueki, M.; Ueno, K.; Miyadoh, S.; Abe, K.; Shibata, K.; Taniguchi, M.; Oi, S. UK-1, a novel cytotoxic metabolite from Streptomyces sp. 517-02. I. Taxonomy, fermentation, isolation, physic-chemical and biological properties. J. Antibiot., 1993, 46, 1089.
[8]
Sato, S.; Kajiura, T.; Noguchi, M.; Takehana, K.; Kobayasho, T.; Tsuji, T. AJ-19591, a new cytotoxic benzoxazole derivative produced by Streptomyces sp. J. Antibiot., 2001, 54, 102.
[9]
Kumar, D.; Jacob, M.; Reynolds, M.; Kerwin, S. Synthesis and Evaluation of Anticancer Benzoxazoles and Benzimidazoles Related to UK-1. Bioorg. Med. Chem., 2002, 10, 3997-4004.
[10]
Rodriguez, A.; Ramirez, C.; Rodriguez, I.; Gonzalez, E. Novel antimycobacterial benzoxazole alkaloids, from the west Indian Sea whip Pseudopterogorgia elisabethae. Org. Lett., 1999, 1, 527-530.
[11]
Rodriguez, I.; Rodrigueza, A.; Wang, Y. Franzblau, S. Ileabethoxazole: a novel benzoxazole alkaloid with antimycobacterial activity. Tetra. Lett., 2006, 47, 3229-3232.
[12]
Don, M.; Shen, C.C.; Lin, Y.; Syu, W.; Ding, H.; Sun, C. Nitrogen-containing compounds from Salvia miltiorrhiza. J. Nat. Prod., 2005, 68, 1066-1070.
[13]
Zawahir, S.; Roberts, D.; Palangasinghe, C.; Mohamed, F.; Eddleston, M.; Dawson, A.; Buckley, N.; Ren, L.; Medley, G.; Gawarammana, I. Acute intentional self-poisoning with a herbicide product containing fenoxaprop-P-ethyl, ethoxysulfuron and isoxadifen ethyl. A prospective observational study. Clin. Toxicol. (Phila.), 2009, 47, 792-797.
[14]
Hohmann, C.; Schneider, K.; Bruntner, C.; Irran, E.; Nicholson, G.; Bull, A.; Jones, A.; Brown, R.; Stach, J.; Goodfellow, M.; Beil, W.; Kramer, M.; Imhoff, J.; Sussmuth, R.; Fiedler, H. Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces sp. NTK 937. J. Antibiot., 2009, 42, 1-6.
[15]
Pressman, B. Biological applications of ionophores. Annu. Rev. Biochem., 1976, 45, 501-530.
[16]
Q., Wu Liang, J.; Lin, S.; Zhou, X.; Bai, L.; Deng, Z.; Wang, Z. Characterization of the biosynthesis gene cluster for the pyrrole polyether antibiotic calcimycin (A23187) in Streptomyces chartreusis NRRL 3882. Antimicrob. Agents Chemother., 2011, 55, 974-982.
[17]
Bennett, T.; Bray, D.; Nevill, M. Suvorexant, a dual orexin receptor
antagonist for the management of insomnia. Drug Forcast, 2014,
39, 266. 2014.
[18]
Satyendra, R.; Vishnumurthy, K.; Vagdevi, H.; Rajesh, K.; Manjunatha, H.; Shruthi, A. Synthesis, in vitro antioxidant, anthelmintic and molecular docking studies of novel dichloro substituted benzoxazole-triazolo-thione derivatives. Eur. J. Med. Chem., 2011, 46, 3078-3084.
[19]
Ongarora, D.; Gut, J.; Rosenthal, P.; Masimirembwa, C.; Kelly, C. Benzoheterocyclicamodiaquine analogues with potent antiplasmodial activity: Synthesis and pharmacological evaluation. Bioorg. Med. Chem. Lett., 2012, 22, 5046-5050.
[20]
Brown, R.; Cameron, R.; Chalmers, D.; Hamilton, S.; Luttick, A.; Krippner, G.; McConnell, D.; Nearn, R.; Stanislawski, P.; Tucker, S.; Watson, K. 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. Bioorg. Med. Chem. Lett., 2005, 15, 2051-2055.
[21]
Zhou, S.; Rynearson, K.; Ding, K.; Brunn, N.; Hermann, T. Screening for inhibitors of the hepatitis C virus internal ribosome entry site RNA. Bioorg. Med. Chem., 2013, 21, 6139-6144.
[22]
Jonckers, T.; Rouan, M.; Hache, G.; Schepens, W.; Hallenberger, S.; Baumeister, J.; Sasaki, J. Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors. Bioorg. Med. Chem. Lett., 2012, 22, 4998-5002.
[23]
Sheng, C.; Xu, H.; Wang, W.; Cao, Y.; Dong, G.; Wang, S.; Che, X.; Ji, H.; Miao, Z.; Yao, J.; Zhang, W. Design, synthesis and antifungal activity of isosteric analogues of benzo heterocyclic N-myristoyltransferase inhibitors. Eur. J. Med. Chem., 2010, 4, 3531-3540.
[24]
Sheng, C.; Che, X.; Wang, W.; Wang, S.; Cao, Y.; Yao, J.; Miao, Z.; Zhang, W. Design and synthesis of antifungal benzoheterocyclic derivatives by scaffold hopping. Eur. J. Med. Chem., 2011, 46, 1706-1712.
[25]
Kuroyanagi, J.; Kanai, K.; Sugimoto, Y.; Horiuchi, T.; Achiwa, I.; Takeshita, H.; Kawakami, K. 1,3-Benzoxazole-4-carbonitrile as a novel antifungal scaffold of b-1,6-glucan synthesis inhibitors. Bioorg. Med. Chem., 2010, 18, 7593-7606.
[26]
Daboit, T. Stopiglia, C.; Carissimi,M.; Corbellini, V.; Stefani, V.; Scroferneker, V. In vitro antifungal activity of 2-(2′-hydroxy-5′-aminophenyl) benzoxazole in Candida spp. Strains. Mycoses, 2009, 52, 507-510.
[27]
Yang, Z.; Fairfax, D.; Maeng, J.; Masih, L.; Usyatinsky, A.; Hassler, C.; Isaacson, S.; Fitzpatrick, K.; Deorazio, R.; Chen, J.; Harding, J.; Isherwood, M.; Dobritsa, S.; Christensen, K.; Wierschke, J.; Bliss, B.; Peterson, L.; Beer, C.; Cioffi, C.; Lynch, M.; Rennells, W.; Richards, J.; Rust, T.; Khmelnitsky, Y.; Cohen, M.; Manning, D. Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists. Bioorg. Med. Chem. Lett., 2010, 20, 6538-6541.
[28]
Lopez-Tudanca, P.; Labeaga, L.; Innerarity, A.; Alonso-Cires, L.; Tapia, I.; Mosquera, R.; Orjales, A. Synthesis and Pharmacological Characteri,zation of a New Benzoxazole Derivative as a Potent 5-HT3 Receptor Agonist. Bioorg. Med. Chem., 2003, 11, 2709-2714.
[29]
Yoshida, S.; Watanabe, T.; Sato, Y. Regulatory molecules for the 5-HT3 receptor ion channel gating system. Bioorg. Med. Chem., 2007, 17, 3515-3523.
[30]
Liu, K.; Lo, J.; Comery, T.; Zhang, G.; Zhang, J.; Kowal, D.; Smith, D.; Di, L.; Kerns, E.; Schechter, L.; Robichaud, A. Identification of a series of benzoxazoles as potent 5-HT6 ligands. Bioorg. Med. Chem. Lett., 2009, 19, 1115-1117.
[31]
Geldern, T.; Lai, C.; Gum, R.; Daly, M.; Sun, C.; Fry, E.; Zapatero, C. Benzoxazole benzenesulfonamides are novel allosteric inhibitors of fructose-1,6bisphosphatase with a distinct binding mode. Bioorg. Med. Chem. Lett., 2006, 16, 1811-1815.
[32]
Gim, H.; Cheon, Y.; Ryu, J.; Jeon, R. Design and synthesis of benzoxazole containing indole analogs as peroxisome proliferator-activated receptor-c/d dual agonists. Bioorg. Med. Chem. Lett., 2011, 21, 3057-3061.
[33]
Chandrasekharappa, A.; Badiger, S.; Dubey, P.; Panigrahi, S.; Reddy, S.; Manukonda, V. Design and synthesis of 2-substituted benzoxazoles as novel PTP1B inhibitors. Bioorg. Med. Chem. Lett., 2013, 23, 2579-2584.
[34]
Omori, N.; Kouyama, N.; Yukimasa, A.; Watanabe, K.; Yokota, Y.; Tanioka, H.; Nambu, H.; Yukioka, H.; Sato, N.; Tanaka, Y.; Sekiguchi, K.; Okuno, T. Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist. Bioorg. Med. Chem. Lett., 2012, 22, 2020-2023.
[35]
Kley, J.; Mack, J.; Hamilton, B.; Scheuerer, S.; Redemann, N. Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure. Bioorg. Med. Chem. Lett., 2011, 21, 5924-5927.
[36]
Topcu, G.; Turkmen, Z.; Schilling, J. Cytotoxic Activity of Some Anatolian Salvia. Extracts and Isolated Abietane Diterpenoids. Pharm. Biol., 2008, 46, 180-184.
[37]
McKee, M.; Kerwin, S. Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(20 hydroxyphenyl)benzoxazole analogs of UK-1. Bioorg. Med. Chem., 2008, 16, 1775-1783.
[38]
Kamal, A.; Reddy, K.; Khan, M.; Shett, I. R.; Ramaiah, J.; Pushpavalli, S.; Srinivas, C.; Pal-Bhadra, M.; Chourasia, M.; Sastry, G.; Juvekar,A.; Zingde, S.; Barkume, M. Synthesis, DNA-binding ability and anticancer activity of benzothiazole/benzoxazole–pyrrolo[2,1-c] [1,4]benzodiazepine conjugates. Bioorg. Med. Chem., 2010, 18, 4747-4761.
[39]
Huang, S.; Hsei, I.; Chen, C. Synthesis and anticancer evaluation of bis(benzimidazoles), bis(benzoxazoles), and benzothiazoles. Bioorg. Med. Chem., 2006, 14, 6106-6119.
[40]
Courtney, S.; Hay, P.; Buck, R.; Colville, C.; Phillips, D.; Scopes, D.; Pollard, D.; Page, M.; Bennett, J.; Hircock, M.; McKenzie, E.; Bhaman, M.; Felix, R.; Stubberfield, C.; Turner, P. Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor. Bioorg. Med. Chem. Lett., 2005, 15, 2295-2299.
[41]
Wang, B.; Maghami, N.; Goodlin, V.; Smith, P. Critical structural motif for the catalytic inhibition of human topoisomerase II by UK-1 and analogs. Bioorg. Med. Chem. Lett., 2004, 14, 3221-3226.
[42]
Salo, H.; Laitinen, T.; Poso, A.; Jarho, E.; Kakkonen, M. Identification of novel SIRT3 inhibitor scaffolds byvirtual screening. Bioorg. Med. Chem. Lett., 2013, 23, 2990-2995.
[43]
Peel, R.; Milstead, M.; Sternbach, D.; Besterman, J.; Leitner, P.; Morton, B. Novel A-ring modified camptothecins as topoisomerase I inhibitors. Bioorg. Med. Chem. Lett., 1995, 5, 2129-2132.
[44]
Gerspacher, M.; Furet, P.; Soldermann, C.; Gaul, C.; Holzer, P.; Vangrevelinghe, E.; Lang, M.; Erdmann, D.; Radimerski, T.; Regnier, C.; Chene, P.; Pover, A.; Hofmann, F.; Baffert, F.; Buhl, T.; Aichholz, R.; Blasco, F.; Endres, R.; Trappe, J.; Drueckes, P. 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 1724-1727.
[45]
Schreiner, E.; Wolff, B.; Winiski, A.; Billich, A. 6-(2-Adamantan-2-ylidene-hydroxybenzoxazole)-O-sulfamate: A potent non-steroidal irreversible inhibitor of human steroid sulfatase. Bioorg. Med. Chem. Lett., 2003, 13, 4313-4316.
[46]
Abdelgawad, M.; Belal, A.; Omar, H.; Hegazy, L.; Rateb, M. Synthesis, anti-breast cancer activity and molecular modeling of some benzothiazole and benzoxazole derivatives. Arch. Pharm. Chem. Life Sci., 2013, 346, 534-541.
[47]
Russo, F.; Romeo, G.; Santagatil, N.; Caruso, A.; Cutuli, V.; Amore, D. Synthesis of new thienopyrimidobenzothiazoles and thienopyrimidobenzoxazoles with analgesic and antiinflammatory properties. Eur. J. Med. Chem., 1994, 29, 569-578.
[48]
Kablaoui, N.; Patel, S.; Shao, J.; Demian, D.; Hoffmaster, K.; Berlioz, F.; Vazquez, M.; Moore, W.; Nugent, R. Novel benzoxazole inhibitors of mPGES-1. Bioorg. Med. Chem. Lett., 2013, 23, 907-911.
[49]
Eren, G. G.; Unlü, S.; Nuñez, M.; Labeaga, L.; Ledo, F.; Entrena, A.; Banoglu, E.; Costantino, G.; Sahin, M. Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors. Bioorg. Med. Chem., 2010, 18, 6367-6376.
[50]
Walker, D.; Arhancet, G.; Lu, H.; Heasley, S.; Metz, S.; Kablaoui, N.; Franco, F.; Hanau, C.A.; Scholten, J.; Springer, J.; Fobian, Y.; Carter, J.; Xing, L.; Yang, S.; Shaffer, A.; Jerome, G.; Baratta, M.; Moore, W.; Vazquez, M. Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: Use of a conformation-based hypothesis to facilitate compound design. Bioorg. Med. Chem. Lett., 2013, 23, 1120-1126.
[51]
Wang, B.; Vernier, J.; Rao, S.; Chung, J.; Anderson, J.; Brodkin, J.; Jiang, X.; Gardner, M.; Yanga, X.; Munoz, B. Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg. Med. Chem., 2004, 12, 17-21.
[52]
Unlu, S.; Baytasa, S.; Kupelib, E.; Yesilada, E. Studies on novel 7-acyl-5-chloro-2-oxo-3H-benzoxazole derivatives as potential analgesic and anti-Inflammatory agents. Arch. Pharm. Pharm. Med. Chem., 2003, 336, 310-321.
[53]
Praveen, C.; Nandakumar, A.; Dheenkumar, P.; Murlidharan, D.; Perumal, P. Microwave-assisted one-pot synthesis of benzothiazole and benzoxazole libraries as analgesic agents. J. Chem. Sci., 2012, 124, 609-624.
[54]
Abdou, W.; Barghash, R.; Sediek, A. Design of new arylamino-2-ethane-1,1-diyl- and benzoxazole-2 methylenebisphosphonates vs cytotoxicity and chronic inflammation diseases. Eur. J. Med. Chem., 2012, 57, 362-372.
[55]
Vinsova, J.; Horak, V.; Buchta, V.; Kaustova, J. Highly Lipophilic Benzoxazoles with Potential Antibacterial Activity. Molecules, 2005, 10, 783-793.
[56]
Vinsova, J.; Cermakova, K.; Tomeckova, A.; Ceckova, M.; Jampilek, J.; Cermak, P.; Kunes, J.; Dolezal, M.; Staud, F. Synthesis and antimicrobial evaluation of new 2-substituted 5,7-di-tert-butylbenzoxazoles. Bioorg. Med. Chem., 2006, 14, 5850-5865.
[57]
Pichota, A.; Duraiswamy, J.; Yin, Z.; Keller, T. Peptide deformylase
inhibitors of Mycobacterium tuberculosis: Synthesis, structural
investigations, and biological results. Bioorg. Med. Chem. Lett.,
2008, 18, 6568-6572.
[58]
Rodríguez, I.I.; Rodríguez, A.D. Homopseudopteroxazole, a new
antimycobacterial diterpene alkaloid from Pseudopterogorgia elisabethae.
J. Nat. Prod., 2003, 66, 855-857.
[59]
Vodela, S.; Reddy Mekala, R.; Reddy Danda, R.; Kodhati, V. Design,
synthesis and screening of some novel benzoxazole based
1,3,4-oxadiazoles as potential antimicrobial agents. Chin. Chem.
Lett., 2013, 24, 625-628.
[60]
Arpac, O.; Yildiz, I.; Ozkan, S.; Kaynak, F.; Sxener, E.; Yalcinet, I. Synthesis and biological activity of some new benzoxazoles. Eur. J. Med. Chem., 2008, 43, 1423-1431.
[61]
Ertan, T.; Yildiz, I.; Gulbas, B.; Bolelli, K.; Arpaci, O.; Ozkan, S.; Kaynak, F.; Yalcin, F.; Aki, E. Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. Eur. J. Med. Chem., 2009, 44, 501-510.
[62]
Padalkar, V.; Borse, B.; Gupta, V.; Phatangare, K.; Patil, V.; Umape, P.; Sekar, N. Synthesis and antimicrobial activity of novel 2-substituted benzimidazole, benzoxazole and benzothiazole derivatives. Asian J. Chem., 2012, 56, 324-326.
[63]
Sum, P.; How, D.; Torres, N.; Newman, H.; Petersen, P.; Mansour, T. Synthesis and Activity of Novel Benzoxazole Derivatives of Mannopeptimycin Glycopeptide Antibiotics. Bioorg. Med. Chem. Lett., 2003, 13, 2607-2610.
[64]
Aki-Seren;Yildiz-Oren.; Tekiner-Gulbas.; Yalcin, I.; Temiz-Arpaci.; Altanlar, N. Synthesis and Antimicrobial Activity of New 2-[p-Substituted-benzyl]-5-[substituted-carbonylamino]benzoxazoles. Arch. Pharm. (Weinheim), 2004, 337, 402-410.
[65]
Balaswamy, G.; Shrinivas, K.; Pradeep, P.; Sarangpani, M. Synthesis, characterization and antimicrobial activity of novel substituted benzoxazole derivatives. Int. J. Chem. Sci., 2012, 10, 619-626.
[66]
Song, H.; Oh, S.; Lee, H.; Han, G.; Kim, J.; Chang, H.; Doh, K.; Rhee, H.; Choo, H. Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg. Med. Chem., 2010, 18, 7580-7585.
[67]
Setoguchi, M.; Iimura, S.; Sugimoto, Y.; Yoneda, Y.; Chiba, J.; Watanabe, T.; Muro, F.; Iigo, Y.; Takayama, G.; Yokoyama, M.; Taira, T.; Aonuma, M. Takashi, t.; Nakayama, A.; Machinaga, N. A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid. Bioorg. Med. Chem., 2013, 21, 42-61.
[68]
Setoguchi, M.; Iimura, S.; Sugimoto, Y.; Yoneda, Y.; Chiba, J.; Watanabe, T.; Muro, F.; Iigo, Y.; Takayama, G.; Yokoyama, M.; Taira, T.; Aonuma, M. Takashi, t.; Nakayama, A.; Machinaga, N. Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl] acetyl]-(4S)-fluoro-(2S) pyrrolidinylmethoxy]cyclohexanecarboxylic acidas a potent, orally active VLA-4 antagonist. Bioorg. Med. Chem., 2012, 20, 1201-1212.
[69]
Lin, L.; Lanza, T.; Castonguay, L.; Kamenecka, T.; McCauley, E.; Riper, G.; Egger, L.; Mumford, R.; Tong, X.; MacCoss, M.; Schmidt, J.; Hagmann, W. Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4. Bioorg. Med. Chem. Lett., 2004, 14, 2331-2334.
[70]
Smith, C.; Ali, A.; Chen, L.; Hammond, M.; Anderson, M.; Chen, Y.; Eveland, S.; Guo, Q.; Hyland, S.; Milot, D.; Sparrow, C.; Wright, S.; Sinclair, P. 2-Arylbenzoxazoles as CETP inhibitors: Substitution of the benzoxazole moiety. Bioorg. Med. Chem. Lett., 2010, 20, 346-349.
[71]
Sweis, R.; Hunt, J.; Kallashi, F.; Hammonda, M.; Chen, Y.; Eveland, S.; Guo, Q.; Hyland, S.; Milot, D.; Cumiskey, A.; Latham, A.; Rosa, R.; Peterson, L.; Sparrow, C.; Wright, S.; Anderson, M.; Sinclair, P. 2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: Scaffold design and advancement in HDLc-raising efficacy. Bioorg. Med. Chem. Lett., 2011, 21, 1890-1895.
[72]
Sweis, R.; Hunt, J.; Sinclair, P.; Chen, Y.; Eveland, S.; Guo, Q.; Hyland, S.; Milot, D.; Cumiskey, A.; Latham, M.; Rosa, R.; Peterson, L.; Sparrow, C.; Anderson, M. 2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: Attenuation of hERG binding and improved HDLc-raising efficacy. Bioorg. Med. Chem. Lett., 2011, 21, 2597-2600.
[73]
Harikrishnan, L.; Kamau, M.; Herpin, T.; Morton, G.; Liu, Y.; Cooper, C.; Salvati, M.; Qiao, J.; Wang, T.; Adam, L.; Taylor, D.; Chen, A.; Yin, X.; Seethala, R.; Peterson, T.; Nirschl, D.; Miller, A.; Weigelt, C.; Appiah, K.; Connell, J.; Lawrence, R. 2-Arylbenzoxazoles as novel cholesteryl ester transferprotein inhibitors: Optimization via array synthesis. Bioorg. Med. Chem. Lett., 2008, 18, 2640-2644.
[74]
Kallashi, F.; Kim, D.; Kowalchick, J.; Park, Y.; Hunt, J.; Ali, A.; Smith, C.; Hammond, M.; Pivnichny, J.; Tong, X.; Xu, S.; Anderson, M.; Chen, Y.; Eveland, S.; Guo, Q.; Hyland, S.; Milot, D.; Cumiskey, A.; Latham, M.; Peterson, M.; Rosa, R.; Sparrow, C.; Wright, S.; Sinclair, P. 2-Arylbenzoxazoles as CETP inhibitors: Raising HDL-C in CETP transgenic mice. Bioorg. Med. Chem. Lett., 2011, 21, 558-561.
[75]
Misra, R.; Barthwal, J.; Parmar, S.; Brumleve, S. Substituted benzoxazole/benzthiazole-2-thiones: Interrelationship between anticonvulsant activity and inhibition of nicotinamide adenine dinucleotide-dependent oxidations and monoamine oxidase. J. Pharm. Sci., 1974, 6, 401-404.
[76]
Misra, R.; Barthwal, J.; Parmar, S.; Singh, S.; Stenberg, V. Synthesis of Substituted Thiobenzoxazoles/Benzothiazoles: Inhibition of Cellular Respiratory and Monoamine Oxidase Activities and Anticonvulsant Property. J. Pharm. Sci., 1976, 65, 405-409.
[77]
Deng, G.; Meng, Q.; Liu, Q.; Xu, X.; Xu, Q.; Ren, F.; Guo, T.; Lu, H.; Xiang, J.; Elliott, J.; Lin, X. Identification of benzoxazole analogs as novel, S1P3 sparing S1P1 agonists. Bioorg. Med. Chem. Lett., 2012, 22, 3973-3977.
[78]
Kim, M. Jeon, J777.; Song, J.; Suh, K.; Kim, Y.; Min, K.; Lee, K. Synthesis of proline analogues as potent and selective cathepsin S inhibitors. Bioorg. Med. Chem. Lett., 2013, 23, 3140-3144.
[79]
Sun, L.; Chen, J.; Bruce, M.; Deskus, J.; Epperson, J.; Takaki, K.; Johnson, G.; Iben, L.; Mahle, C.; Ryan, E.; Xu, C. Synthesis and structure–activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg. Med. Chem. Lett., 2004, 14, 3799-3802.
[80]
Sun, L.; Chen, J.; Takaki, K.; Johnson, G.; Iben, L.; Mahle, C.; Ryan, E.; Xu, C. Design and synthesis of benzoxazole derivatives as novel melatoninergic ligands. Bioorg. Med. Chem. Lett., 2004, 14, 1197-1200.
[81]
Sam, J.; Plampin, J. Benzoxazoles: Potent skeletal muscle relaxants. J. Pharm. Sci., 1964, 53, 538-544.
[82]
Jin, C.; Fix, S.; Kepler, J.; Cook, E. Synthesis and antihormonal properties of novel 11β-benzoxazole-substituted steroids. Bioorg. Med. Chem. Lett., 2012, 22, 1705-1708.
[83]
Xue, C.; Rafalski, M.; Roderick, J.; Eyermann, C.; Mousa, S.; Olson, R.; DeGrado, W. Design, synthesis and in vitro activity of series of benzimidazole/benzoxazole glycoprotein IIb/IIIa inhibitors. Bioorg. Med. Chem. Lett., 1996, 6, 339-344.
[84]
Proenca, C.; Serralheiro, M.; Araujo, M.; Pamplona, T.; Santos, S.; Santos, M.; Frazao, F. Novel sulfenamides as promising acetylcholinesterase inhibitors. J. Heterocycl. Chem., 2011, 48, 1287-1295.
[85]
Cho, S.; Han, S.; Ha, J.; Ryu, J.; Lee, C.; Jung, H.; Kang, N.; Kim, H.; Koh, J.; Lee, J. Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 4223-4227.
[86]
Sessions, E.; Yin, Y.; Bannister, T.; Weiser, A.; Griffin, E.; Pocas, J.; Cameron, M.; Ruiz, C.; Lin, L.; Schürer, S.; Schröter, T.; LoGrasso, P.; Feng, Y. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. Bioorg. Med. Chem. Lett., 2008, 18, 6390-6393.
[87]
Berta, D.; Villa, M.; Vulpetti, A.; Felder, E. Pyrazolyl–benzoxazole derivatives as protein kinase inhibitor: Design and validation of a combinatorial library. Tetrahedron, 2005, 61, 10801-10810.
Download PDF Flyer